biostudies-literatureUnknown11(3)Di Federico AEpidermal growth factor receptor (<i>EGFR</i>) gene fusions represent an extremely rare aberration, occurring in approximately 0.05-0.13% non-small cell lung cancer (NSCLC) patients. <i>RAD51</i> is the most frequently involved partner gene in <i>EGFR</i> fusions, but other fusion partner genes have been described. To date, a considerable number of next-generation sequencing (NGS) panels still cannot detect these alterations due to the position of the breakpoint site, mainly involving intron 24 of <i>EGFR</i>. Current evidences show that such gene alteration is more likely to occur in lung adenocarcinomas of young, female, non-smoker patients. Also, brain metastases are frequently reported in these patients. Only very few cases in literature described clinical characteristics and outcomes Translational lung cancer research497-503https://www.ebi.ac.uk/biostudies/studies/S-EPMC8988076biostudies-literature<i>EGFR</i>-<i>RAD51</i> gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature.PMC8988076Di Federico AGelsomino FDe Giglio APalladini AGiusti RArdizzoni APiras MFiletti Mfalse<i>EGFR</i>-<i>RAD51</i> gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature.Epidermal growth factor receptor (<i>EGFR</i>) gene fusions represent an extremely rare aberration, occurring in approximately 0.05-0.13% non-small cell lung cancer (NSCLC) patients. <i>RAD51</i> is the most frequently involved partner gene in <i>EGFR</i> fusions, but other fusion partner genes have been described. To date, a considerable number of next-generation sequencing (NGS) panels still cannot detect these alterations due to the position of the breakpoint site, mainly involving intron 24 of <i>EGFR</i>. Current evidences show that such gene alteration is more likely to occur in lung adenocarcinomas of young, female, non-smoker patients. Also, brain metastases are frequently reported in these patients. Only very few cases in literature described clinical characteristics and outcomes 2022-01-01T00:00:00Z2022 Mar2025-04-04T10:45:19.906Z2025-04-04T10:45:19.906ZS-EPMC89880763539957410.21037/tlcr-21-888